Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab Via the Ommaya Reservoir in Breast Cancer With Leptomeningeal Metastasis: a Phase II Multicenter Clinical Trial
The First Affiliated Hospital with Nanjing Medical University
26 participants
Oct 27, 2025
INTERVENTIONAL
Conditions
Summary
Evaluate the efficacy and safety of Intrathecal Administration of Thiotepa in Combination with Trastuzumab via the Ommaya Reservoir in Breast Cancer with Leptomeningeal Metastasis
Eligibility
Inclusion Criteria8
- Histologically or cytologically confirmed HER-2 positive breast cancer (immunohistochemistry indicates HER-2 3+ and/or fluorescence in situ hybridization indicates HER-2 gene amplification)
- Diagnosed with breast cancer with leptomeningeal metastasis based on cerebrospinal fluid cytology combined with central nervous system function and brain imaging findings
- The patient has an Ommaya reservoir implanted or is eligible for implantation
- KPS ≥ 30
- Adequate bone marrow and liver and kidney function reserves: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin ≥ 90 g/L. International normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN. Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN. Total serum bilirubin ≤ 1.5 x ULN (patients with Gilbert's syndrome can be enrolled if total bilirubin \< 3 x ULN). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; if the patient has liver metastasis, this criterion is AST and ALT ≤ 5 x ULN.
- Female, aged between 18 and 75 years old
- Left ventricular ejection fraction (LVEF) \> 50%
- Voluntary signing of informed consent form
Exclusion Criteria8
- Patients meeting any of the following criteria are not eligible to be included in this study:
- Subjects with other malignant tumors, excluding skin basal cell carcinoma and carcinoma in situ
- Presence of severe or uncontrollable systemic diseases, including uncontrollable hypertension or active bleeding tendency
- Patients judged by the investigator to be unsuitable for participation in the trial, or those with factors that may affect the patient's compliance with the protocol
- Toxicity caused by previous treatment has not recovered to normal state or is grade 1 according to NCI-CTCAE 5.0
- Allergic to or with metabolic disorders to the drugs in this protocol
- Pregnant or lactating women, or women with pregnancy plans during the study period and within 6 months after the last administration
- Patients participating in other clinical studies simultaneously
Interventions
Intrathecal chemotherapy group Patients received intrathecal 150mg Trastuzumab combination with 10mg thiotepa once every three weeks until an event that meets the criteria for termination occurs.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07263425